About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« USPTO News: Patent Office Posts Comments on New Appeals Rules | Main | Conference & CLE Calendar »

September 12, 2008

Biotech/Pharma Lobbying Scoreboard - Second Quarter Update - Part II

    By Donald Zuhn --

Last month, we reported on the lobbying expenditures for fourteen biotech and pharma companies and organizations in the second quarter of 2008.  Recent news reports have allowed us to add four more companies to the list:

Sanofiaventis_large • Sanofi-Aventis' U.S. subsidiary spent more than $1.2 million on second quarter lobbying (see Forbes.com report).  According to Sanofi-Aventis' July 18 filing with the House clerk's office, the drugmaker's lobbying efforts were directed in part at follow-on biologics legislation.  In addition, the company's vaccine division spent $460,000 lobbying in part on patent reform.

Teva_1 • Teva Pharmaceutical Industries Inc. spent $490,000 on second quarter lobbying (see Forbes.com report).  According to Teva's July 18 filing with the House clerk's office, the generic drugmaker's lobbying efforts were directed in part at patent reform and follow-on biologics legislation.

Allergan • Allergan Inc. spent $410,000 on second quarter lobbying (see Forbes.com report).  According to Allergan's July 21 filing with the House clerk's office, the biotech company's lobbying efforts were directed in part at follow-on biologics legislation.

Watson_pharmaceuticals • Watson Pharmaceuticals Inc. spent $230,000 on second quarter lobbying (see Forbes.com report).  According to Watson's July 21 filing with the House clerk's office, the generic drugmaker's lobbying efforts were directed in part at follow-on biologics legislation.

Patent Docs readers are reminded that in our previous report, we also highlighted the lobbying esxpenditures of a number of IT companies and organizations as a point of comparison with the the lobbying expenses of various members of the biotech/pharma industry (see "Biotech/Pharma Lobbying Scoreboard - Second Quarter Update").

For additional information regarding this topic, please see:

• "Biotech/Pharma Lobbying Scoreboard - Second Quarter Update," August 21, 2008
• "Biotech/Pharma Lobbying Scoreboard - Part II," June 30, 2008
• "Biotech/Pharma Lobbying Scoreboard" June 6, 2008
• "Lobbying Spending Spree Continues," May 20, 2008
• "Abbott's First Quarter Lobbying Tab Hits $880,000," May 2, 2008

Posted at 11:35 PM in Biosimilars, Patent Legislation |

Comments

The comments to this entry are closed.

November 2024

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Categories

Archives

More...